Precirix

Precirix Receives FDA Clearance to Begin Phase 1 Trial of CAM-FAP-Ac-225 Targeted Alpha Therapy

- The FDA has accepted Precirix's IND application for CAM-FAP-Ac-225, a novel targeted alpha therapy combining a FAP-targeting antibody with Actinium-225 for treating solid tumors. - CAM-FAP-Ac-225 targets fibroblast activation protein (FAP), which is highly expressed in cancer-associated fibroblasts across a broad range of epithelial tumors. - The clearance enables Precirix to initiate a Phase 1 clinical trial evaluating safety, tolerability, dosimetry, and preliminary efficacy in patients with FAP-positive advanced solid tumors. - The alpha particles from Actinium-225 provide high linear energy transfer, enabling potent localized cytotoxicity with minimal off-target effects.